Psoriatic arthritis (PsA) is a long-lasting disease that causes swelling in the joints and skin of people with psoriasis, a skin condition that causes itchy, red patches. This study aims to see how well a new medicine called zasocitinib works for people with active PsA who haven't tried biologic medicines before. Participants will get zasocitinib, another active medicine, or a placebo (a pill with no medicine) for up to 60 weeks.
Key Points:
- Duration: Up to 60 weeks participation
- Treatment: Zasocitinib, active comparator, or placebo
- Eligibility: Adults with active PsA, not treated with biologic medicines before
To be part of the study, you need to be 18 years or older and have had PsA symptoms for at least 3 months. You must have at least 3 tender and 3 swollen joints, and at least one skin patch from psoriasis. You should not have other diseases like rheumatoid arthritis or certain skin conditions that could confuse the results. If you have tried and not improved with regular PsA medicines, you might qualify.